The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

The gush of second quarter earnings reports is beginning to slow to a trickle, and with most of the reports in, the results ...

The gush of second quarter earnings reports is beginning to slow to a trickle, and with most of the reports in, the results ...

This FTSE 100 stock could be on the verge of stealing enormous chunks of market share from some of the largest pharmaceutical ...